T. Greten
Hepatology · 2005–2021
A researcher in the Science corpus: 12 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Hepatology — 138 citations into it
Whom T. Greten trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from T. Greten's perspective
Ordered by how strongly the researchers T. Greten trusts endorse each paper. Same corpus, a different order for every researcher.
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
- Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
- Novel advancements in the management of hepatocellular carcinoma in 2008. (Journal of Hepatology)
- Portal Vein Embolization Before Right Hepatectomy: Prospective Clinical Trial (Annals of Surgery)
- The natural history of compensated cirrhosis due to hepatitis C virus: A 17‐year cohort study of 214 patients (Hepatology)
- Noninvasive assessment of liver fibrosis (Hepatology)
- Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. (Journal of Hepatology)
- INCIDENCE OF HEPATOCELLULAR CARCINOMA AND ASSOCIATED RISK FACTORS IN HEPATITIS C-RELATED ADVANCED LIVER DISEASE (Gastroenterology)
- Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. (Journal of Clinical Oncology)
- Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. (Journal of the American College of Surgeons)
Their papers
- Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells (2018) — 1,289 citations
- Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma (2021) — 840 citations
- Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer (2019) — 723 citations
- Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade (2017) — 5,893 citations
- NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis (2016) — 693 citations
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma (2016) — 749 citations
- Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards (2016) — 2,457 citations
- EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012) — 3,548 citations
- Myeloid Derived Suppressor Cells Inhibit Natural Killer Cells in Patients with Hepatocellular Carcinoma via the NKp30 Receptor (2009) — 634 citations
- Sorafenib in advanced hepatocellular carcinoma. (2008) — 6,212 citations
- A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. (2008) — 822 citations
- Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. (2005) — 673 citations